Abstract
ObjectivesNovel treatments have been developed for relapsed/refractory (r/r) acute leukaemia in children, yet limited evidence exists about the most cost-effective strategies. In this review, we summarized the evidence about costs...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
